EULAR News – June 22, 2018
A final observation from this year’s EULAR meeting
A final observation from this year’s EULAR meeting encouraging to all patients is the emphasis many sessions had on the importance of patient participation and partnerships for achieving research outcomes that are relevant to the actual patients. Many presentations clearly communicated that no matter how complicated the research or how brilliant the researcher, patients can always offer unique, invaluable insights.
Experience in Europe and North America has shown that patient advice when designing, implementing and disseminating research outcomes makes studies more effective, more credible and possibly even more cost efficient.
The benefits of exercise in inflammatory arthritis and osteoarthritis
ACE has frequently written about the benefits of exercise in inflammatory arthritis (IA) and osteoarthritis (OA). During a series of EULAR presentations, speakers provided evidence for regular physical activity for IA and OA patients.
Anne- Kathryn Rausch, an academic from Zurich University, spoke about how general recommendations for physical activity are effective, safe and feasible for patients with ankylosing spondylitis, rheumatoid arthritis, and osteoarthritis.
“New drugs – new perspectives: clinical and regulatory issues concerning biosimilars” – Professor Tore Kvien
During the session, “New drugs – new perspectives: clinical and regulatory issues concerning biosimilars,” Professor Tore Kvien, head of the department of rheumatology at the Diakonhjemmet Hospital in Oslo, updated EULAR delegates on the latest issues and evidence on the use of biosimilars.
ACE is the leader in Canada providing patient information and education on biosimilars. If this therapy is new to you, please visit the Biosim•Exchange area of our website.
ACE is sharing the latest research news from this year’s European League Against Arthritis’ (EULAR) Annual European Congress of Rheumatology in Amsterdam, Netherlands.
ACE is attending this year’s annual meeting of the European League Against Arthritis (EULAR) in Amsterdam, which will be host to 14,000 participants from more than 120 countries in Europe and around the world. This year, EULAR received more than 5,050 research abstracts – the most ever. The meeting will feature over 175 sessions and 45 themed poster tours with more than 560 speakers showcasing work from 2,256 poster displays. ACE is here to learn the most current information on the impact, burden and cost of arthritis for patients and society, and the improved ability to diagnose and treat different types of arthritis early.
Many of these advances are the product of collaboration between healthcare providers and patients and patient organizations like ACE. We will be reporting over the next few days on how this collaboration is advancing models of care and development of advanced therapies.
ACE is also leading a meeting with members of the Global RA Network who are attending EULAR. At the meeting, ACE will facilitate discussion on the development of tools for Global RA Network members to use in their countries to raise awareness and advocate for improved models of care. Based on the 2017 Global RA survey findings, ACE is proposing to develop tools that will improve RA patients’ understanding about the kind and quality of care they should be receiving in their country to improve their disease and overall health.